← Back to Search

Ripasudil Eye Drops for Cataract Surgery

Phase 3
Waitlist Available
Research Sponsored by Kowa Research Institute, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 26
Awards & highlights
Pivotal Trial

Summary

This trial tests K-321 to see if it helps people recover better after cataract surgery. It focuses on ensuring the treatment is safe and effective for these patients.

Eligible Conditions
  • Swelling of the cornea

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 26
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 26 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Central Corneal Endothelial Cell Density (ECD) at Week 12
Secondary study objectives
Change in Best-Corrected Visual Acuity (BCVA)
Change in Central Corneal ECD
Change in Corneal Thickness
+6 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Group BExperimental Treatment1 Intervention
Participants receive K-321 ophthalmic solution Four times daily(QID) for 12 Weeks followed by a 14 week follow-up period with no treatment.
Group II: Group AExperimental Treatment1 Intervention
Participants receive K-321 ophthalmic solution Four times daily(QID) for 12 Weeks followed by a 4 week follow-up period with no treatment.
Group III: Group CPlacebo Group1 Intervention
Participants will receive K-321 Placebo ophthalmic solution QID for 12 Weeks followed by a 4 week follow-up period with no treatment.
Group IV: Group DPlacebo Group1 Intervention
Participants will receive K-321 Placebo ophthalmic solution QID for 12 Weeks followed by a 14 week follow-up period with no treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ripasudil
2022
Completed Phase 3
~340

Find a Location

Who is running the clinical trial?

Kowa Research Institute, Inc.Lead Sponsor
45 Previous Clinical Trials
16,005 Total Patients Enrolled
Shona Pendse, MD, MMScStudy ChairKowa Pharma Development Co.
5 Previous Clinical Trials
483 Total Patients Enrolled
~102 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top